March 22, 2019 – Vancouver, BC – Isodiol Worldwide Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Firm” or “Isodiol”) is satisfied to announce that on the assembly of the earlier shareholders of Kure Corp. (the “Collectors”) held on March 20, 2019 (the “Assembly”), the Collectors in attendance by person or proxy unanimously voted in favour of a selection (the “Association Choice”) to approve the beforehand introduced strategy of association (the “Association”) involving Isodiol, Kure Corp. (“Kure”), and the Collectors pursuant to which Isodiol will distribute all the issued and superb shares of Kure (the “Kure Shares”) to the Collectors and in consideration for the Kure Shares, Isodiol will most likely be absolved of its February 1, 2019 obligation to issue shares obtaining a worth of as a lot as US$35,000,000 to the Collectors.

The Association necessary the approval of: (i) a majority of the Collectors existing in person or by proxy on the Assembly and (ii) not decrease than 75% of the worth of Collectors. Of the votes strong on the Assembly, 100% of the votes strong by Collectors have been in favour of the Association Choice.

Isodiol has obtained a final order from the Supreme Court docket of British Columbia dated March 22, 2019, approving the Association.

Assuming that the situations to closing are satisfied or waived, it is anticipated that the Association will most likely be achieved soon after the shut of obtaining and promoting on March 29, 2019, following which date Kure will now not be a wholly-owned subsidiary of Isodiol.

About Isodiol Worldwide Inc.

Isodiol Worldwide Inc. is targeted on the dietary effectively becoming benefits which are derived from hemp
and is a solution development, gross sales, marketing and distribution firm of hemp-primarily based Client Packaged Things (CPG) and choices. Isodiol has commercialized a 99%+ pure, naturally remoted CBD, collectively with micro-encapsulations, and nano-technologies for higher high-quality consumable and topical skincare merchandise. Isodiol’s progress strategy includes the occasion of more than-thecounter and pharmaceutical medicine and continued worldwide development into Latin America, Asia, and Europe.

Isodiol’s progress strategy includes the occasion of more than-the-counter and pharmaceutical medicine and continued worldwide development into Latin America, Asia, and Europe.

Be a element of Us On Fb: https://www.fb.com/IsodiolInternationalInc/

Twitter: @Isodiolintlinc

ON BEHALF OF THE BOARD

Marcos Agramont, CEO & Director

INVESTOR RELATIONS:

[email protected]

www.isodiol.com

 604-409-4409

Ahead-Attempting Information: This info launch incorporates “forward-searching info” all through the that suggests of relevant securities legal suggestions referring to statements regarding the Firm’s enterprise, proposed association with collectors, merchandise and future the Firm’s enterprise, its solution options and plans for gross sales and marketing. Although the Firm believes that the expectations mirrored inside the forward-searching information are economical, there will be no assurance that such expectations will show to be ideal. Readers are cautioned to not spot undue reliance on forward-searching information. Such forward-searching statements are subject to dangers and uncertainties which will trigger precise outcomes, efficiency and developments to differ materially from these contemplated by these statements relying on, amongst distinctive troubles, the dangers that the Firm’s merchandise and strategy will fluctuate from these mentioned on this info launch and the Firm may possibly not be capable to carry out its enterprise plans as anticipated. Apart from as necessary by legislation, the Firm expressly disclaims any obligation and does not intend, to replace any forward-searching statements or forward-searching information on this info launch. Although the Firm believes that the expectations mirrored inside the forward-searching information are economical, there will be no assurance that such expectations will show to be ideal and tends to make no reference to profitability mainly primarily based on gross sales reported. The statements on this info launch are created as of the date of this launch.

The CSE has not reviewed, accredited or disapproved the content material material of this press launch.